Antihistamines are often tried, but they usually only work half the time. Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade.

The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...

Sanofi and Regeneron’s dupilumab has been given a priority review by the FDA, putting the first-in-class drug on course for a likely approval by 29 March. The drug is for adult patients with ...

has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1 ...

Initiation rates for dupilumab and tezepelumab were similar from 2022 to 2023. Dupilumab and tezepelumab work best with high eosinophil levels. Trends were similar at the study site and patient ...

Surya Bhatt, M.D., an associate professor in the UAB Division of Pulmonary, Allergy, and Critical Care Medicine, reported in the New England Journal of Medicine that patients with COPD and type 2 ...

In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was approved for treatment of chronic spontaneous urticaria in patients aged 12 years and older.

More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...